Susquehanna Portfolio Strategies LLC Sells 12,821 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Susquehanna Portfolio Strategies LLC decreased its position in shares of HealthEquity, Inc. (NASDAQ:HQY) by 33.9% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,999 shares of the company’s stock after selling 12,821 shares during the period. Susquehanna Portfolio Strategies LLC’s holdings in HealthEquity were worth $2,041,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of HQY. Cape Investment Advisory Inc. purchased a new stake in HealthEquity in the fourth quarter worth about $27,000. Rise Advisors LLC purchased a new stake in HealthEquity in the first quarter worth about $28,000. McGlone Suttner Wealth Management Inc. purchased a new stake in HealthEquity in the fourth quarter worth about $29,000. YHB Investment Advisors Inc. purchased a new stake in HealthEquity in the first quarter worth about $40,000. Finally, Fidelis Capital Partners LLC purchased a new stake in HealthEquity in the first quarter worth about $42,000. Institutional investors own 99.55% of the company’s stock.

HealthEquity Price Performance

HQY stock traded up $0.14 during midday trading on Monday, reaching $76.63. The stock had a trading volume of 123,419 shares, compared to its average volume of 603,270. The company’s fifty day simple moving average is $81.42 and its 200 day simple moving average is $79.35. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.44. The company has a market cap of $6.67 billion, a price-to-earnings ratio of 83.14, a price-to-earnings-growth ratio of 1.29 and a beta of 0.57. HealthEquity, Inc. has a 52-week low of $61.32 and a 52-week high of $88.26.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Monday, June 3rd. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The company had revenue of $287.60 million for the quarter, compared to analyst estimates of $278.78 million. HealthEquity had a return on equity of 7.77% and a net margin of 7.71%. As a group, sell-side analysts predict that HealthEquity, Inc. will post 2.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. BTIG Research increased their price target on shares of HealthEquity from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, March 20th. JPMorgan Chase & Co. increased their price target on shares of HealthEquity from $86.00 to $108.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Robert W. Baird upped their price objective on shares of HealthEquity from $98.00 to $104.00 and gave the company an “outperform” rating in a report on Tuesday, June 4th. JMP Securities upped their price objective on shares of HealthEquity from $101.00 to $105.00 and gave the company a “market outperform” rating in a report on Tuesday, June 4th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $92.00 price objective on shares of HealthEquity in a report on Tuesday, June 4th. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, HealthEquity presently has an average rating of “Moderate Buy” and a consensus price target of $101.67.

Insiders Place Their Bets

In related news, Vice Chairman Stephen Neeleman sold 400 shares of the firm’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total transaction of $34,000.00. Following the completion of the sale, the insider now directly owns 90,515 shares of the company’s stock, valued at approximately $7,693,775. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other HealthEquity news, Vice Chairman Stephen Neeleman sold 400 shares of HealthEquity stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $85.00, for a total value of $34,000.00. Following the completion of the transaction, the insider now directly owns 90,515 shares of the company’s stock, valued at approximately $7,693,775. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jon Kessler sold 32,326 shares of HealthEquity stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $82.83, for a total value of $2,677,562.58. Following the completion of the transaction, the chief executive officer now directly owns 232,176 shares of the company’s stock, valued at $19,231,138.08. The disclosure for this sale can be found here. Insiders sold 42,511 shares of company stock valued at $3,519,346 in the last three months. 2.20% of the stock is currently owned by insiders.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.